Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma

Hyun Jung Lee, Jong Eun Yeon, Sang Jun Suh, Sun Jae Lee, Eileen L. Yoon, Keunhee Kang, Yang Jae Yoo, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background/Aims: α-Fetoprotein (AFP) is the biomarker most widely used to detect hepatocellular carcinoma (HCC), despite its suboptimal diagnostic accuracy. Glypican-3 (GPC3) and osteopontin (OPN) are secreted glycoproteins that are reportedly associated with tumorigenesis and metastasis. This study was conducted to evaluate the clinical utility of using plasma GPC3 and OPN as diagnostic biomarkers for HCC. Methods: We measured the plasma levels of GPC3 and OPN in 120 HCC and 40 chronic liver disease (CLD) patients via an enzyme-linked immunosorbent assay. The diagnostic accuracy of each tumor marker was evaluated using receiver operating characteristic (ROC) curve analysis. Results: The GPC3 levels in the HCC patients (75.8 ng/mL) were significantly higher (p=0.020) than the levels in patients with CLD (66.4 ng/mL). The area under the ROC curve (AUROC) values for GPC3 and OPN were 0.62 and 0.51, respectively. In subgroup analyses, including subgroups of HCC patients with low serum AFP and PIVKA II levels, the AUROC of GPC3 remained relatively high (0.66), and GPC3 showed a high sensitivity (62.1%) for detecting small HCC tumors. Conclusions: The plasma levels of GPC3 and OPN demonstrated low diagnostic accuracy for HCC. However, GPC3 may have a complementary role in diagnosing HCC in patients with nondiagnostic levels of conventional tumor markers and with small-sized tumors.

Original languageEnglish
Pages (from-to)177-185
Number of pages9
JournalGut and Liver
Volume8
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Glypicans
Osteopontin
Hepatocellular Carcinoma
Biomarkers
ROC Curve
Fetal Proteins
Tumor Biomarkers
Liver Diseases
Chronic Disease
Area Under Curve
Neoplasms
Glycoproteins
Carcinogenesis
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis

Keywords

  • Glypican-3
  • Hepatocellular carcinoma
  • Osteopontin

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. / Lee, Hyun Jung; Yeon, Jong Eun; Suh, Sang Jun; Lee, Sun Jae; Yoon, Eileen L.; Kang, Keunhee; Yoo, Yang Jae; Kim, Ji Hoon; Seo, Yeon Seok; Yim, Hyung Joon; Byun, Kwan Soo.

In: Gut and Liver, Vol. 8, No. 2, 01.01.2014, p. 177-185.

Research output: Contribution to journalArticle

Lee, Hyun Jung ; Yeon, Jong Eun ; Suh, Sang Jun ; Lee, Sun Jae ; Yoon, Eileen L. ; Kang, Keunhee ; Yoo, Yang Jae ; Kim, Ji Hoon ; Seo, Yeon Seok ; Yim, Hyung Joon ; Byun, Kwan Soo. / Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. In: Gut and Liver. 2014 ; Vol. 8, No. 2. pp. 177-185.
@article{a546abb9789b4d629bd79a0f55fcad73,
title = "Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma",
abstract = "Background/Aims: α-Fetoprotein (AFP) is the biomarker most widely used to detect hepatocellular carcinoma (HCC), despite its suboptimal diagnostic accuracy. Glypican-3 (GPC3) and osteopontin (OPN) are secreted glycoproteins that are reportedly associated with tumorigenesis and metastasis. This study was conducted to evaluate the clinical utility of using plasma GPC3 and OPN as diagnostic biomarkers for HCC. Methods: We measured the plasma levels of GPC3 and OPN in 120 HCC and 40 chronic liver disease (CLD) patients via an enzyme-linked immunosorbent assay. The diagnostic accuracy of each tumor marker was evaluated using receiver operating characteristic (ROC) curve analysis. Results: The GPC3 levels in the HCC patients (75.8 ng/mL) were significantly higher (p=0.020) than the levels in patients with CLD (66.4 ng/mL). The area under the ROC curve (AUROC) values for GPC3 and OPN were 0.62 and 0.51, respectively. In subgroup analyses, including subgroups of HCC patients with low serum AFP and PIVKA II levels, the AUROC of GPC3 remained relatively high (0.66), and GPC3 showed a high sensitivity (62.1{\%}) for detecting small HCC tumors. Conclusions: The plasma levels of GPC3 and OPN demonstrated low diagnostic accuracy for HCC. However, GPC3 may have a complementary role in diagnosing HCC in patients with nondiagnostic levels of conventional tumor markers and with small-sized tumors.",
keywords = "Glypican-3, Hepatocellular carcinoma, Osteopontin",
author = "Lee, {Hyun Jung} and Yeon, {Jong Eun} and Suh, {Sang Jun} and Lee, {Sun Jae} and Yoon, {Eileen L.} and Keunhee Kang and Yoo, {Yang Jae} and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Byun, {Kwan Soo}",
year = "2014",
month = "1",
day = "1",
doi = "10.5009/gnl.2014.8.2.177",
language = "English",
volume = "8",
pages = "177--185",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

TY - JOUR

T1 - Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma

AU - Lee, Hyun Jung

AU - Yeon, Jong Eun

AU - Suh, Sang Jun

AU - Lee, Sun Jae

AU - Yoon, Eileen L.

AU - Kang, Keunhee

AU - Yoo, Yang Jae

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Byun, Kwan Soo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/Aims: α-Fetoprotein (AFP) is the biomarker most widely used to detect hepatocellular carcinoma (HCC), despite its suboptimal diagnostic accuracy. Glypican-3 (GPC3) and osteopontin (OPN) are secreted glycoproteins that are reportedly associated with tumorigenesis and metastasis. This study was conducted to evaluate the clinical utility of using plasma GPC3 and OPN as diagnostic biomarkers for HCC. Methods: We measured the plasma levels of GPC3 and OPN in 120 HCC and 40 chronic liver disease (CLD) patients via an enzyme-linked immunosorbent assay. The diagnostic accuracy of each tumor marker was evaluated using receiver operating characteristic (ROC) curve analysis. Results: The GPC3 levels in the HCC patients (75.8 ng/mL) were significantly higher (p=0.020) than the levels in patients with CLD (66.4 ng/mL). The area under the ROC curve (AUROC) values for GPC3 and OPN were 0.62 and 0.51, respectively. In subgroup analyses, including subgroups of HCC patients with low serum AFP and PIVKA II levels, the AUROC of GPC3 remained relatively high (0.66), and GPC3 showed a high sensitivity (62.1%) for detecting small HCC tumors. Conclusions: The plasma levels of GPC3 and OPN demonstrated low diagnostic accuracy for HCC. However, GPC3 may have a complementary role in diagnosing HCC in patients with nondiagnostic levels of conventional tumor markers and with small-sized tumors.

AB - Background/Aims: α-Fetoprotein (AFP) is the biomarker most widely used to detect hepatocellular carcinoma (HCC), despite its suboptimal diagnostic accuracy. Glypican-3 (GPC3) and osteopontin (OPN) are secreted glycoproteins that are reportedly associated with tumorigenesis and metastasis. This study was conducted to evaluate the clinical utility of using plasma GPC3 and OPN as diagnostic biomarkers for HCC. Methods: We measured the plasma levels of GPC3 and OPN in 120 HCC and 40 chronic liver disease (CLD) patients via an enzyme-linked immunosorbent assay. The diagnostic accuracy of each tumor marker was evaluated using receiver operating characteristic (ROC) curve analysis. Results: The GPC3 levels in the HCC patients (75.8 ng/mL) were significantly higher (p=0.020) than the levels in patients with CLD (66.4 ng/mL). The area under the ROC curve (AUROC) values for GPC3 and OPN were 0.62 and 0.51, respectively. In subgroup analyses, including subgroups of HCC patients with low serum AFP and PIVKA II levels, the AUROC of GPC3 remained relatively high (0.66), and GPC3 showed a high sensitivity (62.1%) for detecting small HCC tumors. Conclusions: The plasma levels of GPC3 and OPN demonstrated low diagnostic accuracy for HCC. However, GPC3 may have a complementary role in diagnosing HCC in patients with nondiagnostic levels of conventional tumor markers and with small-sized tumors.

KW - Glypican-3

KW - Hepatocellular carcinoma

KW - Osteopontin

UR - http://www.scopus.com/inward/record.url?scp=84897004411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897004411&partnerID=8YFLogxK

U2 - 10.5009/gnl.2014.8.2.177

DO - 10.5009/gnl.2014.8.2.177

M3 - Article

VL - 8

SP - 177

EP - 185

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -